Hexokinase 2 antibody (AA 453-483)

Catalog No. ABIN1882090

This Rabbit Polyclonal antibody specifically detects Hexokinase 2 in WB and IHC (p). It exhibits reactivity toward Human and has been mentioned in 5+ publications.

Quick Overview for Hexokinase 2 antibody (AA 453-483) (ABIN1882090)

Target: Hexokinase 2 (HK2)

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Hexokinase 2 antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Clone: RB5333

Product Details anti-Hexokinase 2 Antibody

Binding Specificity: AA 453-483

Purification: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This HK2 (Hexokinase II) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 453-483 amino acids from the Central region of human HK2 (Hexokinase II).

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000. IHC-P: 1:100. IHC-P: 1:100

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

References for anti-Hexokinase 2 antibody (ABIN1882090)

Kiritsy, Antoniades, Carlson, Beaulieu, DAndrea, Lynch et al.: "Combination of platelet-derived growth factor-BB and insulin-like growth factor-I is more effective than platelet-derived growth factor-BB alone in stimulating complete healing of full-thickness..." in: Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, Vol. 3, Issue 3, pp. 340-50, (2006) (PubMed).

Kuwabara, Ishikawa, Kobayashi, Kobayashi, Sugiyama: "Renal clearance of a recombinant granulocyte colony-stimulating factor, nartograstim, in rats." in: Pharmaceutical research, Vol. 12, Issue 10, pp. 1466-9, (1996) (PubMed).

Laakso, Malkki, Deeb: "Amino acid substitutions in hexokinase II among patients with NIDDM." in: Diabetes, Vol. 44, Issue 3, pp. 330-4, (1995) (PubMed).

Echwald, Bjørbaek, Hansen, Clausen, Vestergaard, Zierath, Printz, Granner, Pedersen: "Identification of four amino acid substitutions in hexokinase II and studies of relationships to NIDDM, glucose effectiveness, and insulin sensitivity." in: Diabetes, Vol. 44, Issue 3, pp. 347-53, (1995) (PubMed).

Shinohara, Yamamoto, Kogure, Ichihara, Terada: "Steady state transcript levels of the type II hexokinase and type 1 glucose transporter in human tumor cell lines." in: Cancer letters, Vol. 82, Issue 1, pp. 27-32, (1994) (PubMed).

Target Details for Hexokinase 2

Target: Hexokinase 2 (HK2)

Alternative Name: HK2 (Hexokinase II)

Background: In vertebrates there are four major glucose-phosphorylating isoenzymes, designated hexokinase I, II, III, and IV. Hexokinase is an allosteric enzyme inhibited by its product GLC-6-P. Hexokinase activity is involved in the first step in several metabolic pathways. HK3 is bound to the outer mitochondrial membrane. Its hydrophobic N-terminal sequence may be involved in membrane bindng. It is the predominant hexokinase isozyme expressed in insuline-responsive tissues such as skeletal muscle. The N- and C-terminal halves of this hexokinase show extensive sequence similarity to each other. The catalytic activity is associated with the C-terminus while regulatory function is associated wiht the N-terminus. Although found in NIDDM patients, genetic variations of HK2 do not contribute to the disease.

Molecular Weight: 102380

NCBI Accession: NP_000180

UniProt: P52789

Pathways: PI3K-Akt Signaling, Carbohydrate Homeostasis, Warburg Effect